IL2 and COVID-19: We found that 95.6% (43/45) of COVID-19 patients developed robust SARS-CoV-2-specific IFN-γ-secreting T-cell responses [median: 161 spot-forming cells (SFCs)/5 × 105 PBMCs, IQR: 74, 351 SFCs/5 × 105 PBMCs] and 93.8% (15/16) developed SARS-CoV-2-specific IL-2-secreting T-cell responses (median: 234 SFCs/5 × 105 PBMCs, IQR: 167, 380 SFCs/5 × 105 PBMCs) (Figures 6C,D).